Radioembolization for Hepatocellular Carcinoma using TheraSphere®
Author Information
Author(s): Ali Safiyya Mohamed
Primary Institution: Liver Diseases Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia
Hypothesis
Can TheraSphere® improve outcomes for patients with hepatocellular carcinoma?
Conclusion
Radioembolization with TheraSphere® shows promise but lacks definitive evidence of survival benefits from randomized trials.
Supporting Evidence
- Radioembolization has shown promising outcomes in primary and secondary liver malignancies.
- Studies indicate that TheraSphere® can be safely used in patients with portal vein thrombosis.
- Median survival reported for patients treated with TheraSphere® was 12 months.
- Complete necrosis was observed in 66% of patients after treatment with Y90 therapy.
Takeaway
TheraSphere® is a treatment for liver cancer that uses tiny radioactive beads, but we need more studies to know if it really helps people live longer.
Methodology
This review summarizes existing literature on the efficacy and safety of Y90 therapy using TheraSphere®.
Limitations
No randomized clinical trials have been conducted on TheraSphere®, and existing studies do not show a survival benefit.
Participant Demographics
Patients with unresectable hepatocellular carcinoma, including those with portal vein thrombosis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website